---
document_datetime: 2025-12-02 04:56:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/oprymea.html
document_name: oprymea.html
version: success
processing_time: 0.1255744
conversion_datetime: 2025-12-26 09:35:47.315382
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Oprymea

[RSS](/en/individual-human-medicine.xml/66932)

##### Authorised

This medicine is authorised for use in the European Union

pramipexole Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Oprymea](#more-information-on-oprymea-1485)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Oprymea is a medicine used to treat the symptoms of the following diseases:

- Parkinson's disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness. Oprymea can be used either on its own or in combination with levodopa (another medicine for Parkinson's disease), at any stage of disease including the later stages when levodopa starts becoming less effective;
- moderate to severe restless-legs syndrome, a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night. Oprymea is used when a specific cause for the disorder cannot be identified.

Oprymea contains the active substance pramipexole.

Oprymea is a 'generic medicine'. This means that Oprymea contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Sifrol (also known as Mirapexin).

Expand section

Collapse section

## How is Oprymea used?

Oprymea can only be obtained with a prescription. It is available as immediate-release tablets (0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg and 1.1 mg) and prolonged-release tablets (0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and 3.15 mg). Immediate-release tablets release the active substance into the body immediately, and prolonged-release tablets release it slowly over a few hours.

For Parkinson's disease, the starting dose is either one 0.088 mg immediate-release tablet three times a day or one 0.26 mg prolonged-release tablet once a day. The dose should be increased every five to seven days until symptoms are controlled without causing side effects that cannot be tolerated. The maximum daily dose for the immediate-release tablets is 1.1 mg three times a day and in case of the prolonged release tablets is 3.15 mg once a day. Oprymea must be given less frequently in patients who have problems with their kidneys. If treatment needs to be stopped for any reason, the dose should be decreased gradually.

For restless-legs syndrome, Oprymea immediate-release tablets should be taken once a day, two to three hours before going to bed. The recommended starting dose is one 0.088 mg tablet, but, if needed, this can be increased every four to seven days to reduce symptoms further, to a maximum of three 0.18 mg tablets. The patient's response and the need for further treatment should be evaluated after three months. The prolonged-release tablets are not suitable for restless-legs syndrome.

Oprymea tablets should be swallowed with water. The prolonged-release tablets must not be chewed, divided or crushed, and should be taken around the same time every day.

For more information about using Oprymea, see the package leaflet or contact your doctor or pharmacist.

## How does Oprymea work?

The active substance in Oprymea, pramipexole, is a dopamine agonist, which imitates the action of dopamine. Dopamine is a messenger substance in the parts of the brain that control movement and co?ordination. In patients with Parkinson's disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases. The patients then lose their ability to control their movements reliably. Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the symptoms of Parkinson's disease, such as shaking, stiffness and slowness of movement.

The way pramipexole works in restless-legs syndrome is not fully understood. The syndrome is thought to be caused by problems in the way dopamine works in the brain, which can be corrected by pramipexole.

## How has Oprymea been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Sifrol, and do not need to be repeated for Oprymea.

As for every medicine, the company provided studies on the quality of Oprymea. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Oprymea?

Because Oprymea is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Oprymea authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Oprymea has been shown to have comparable quality and to be bioequivalent to Sifrol. Therefore, the Agency's view was that, as for Sifrol, the benefit of Oprymea outweighs the identified risk and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Oprymea?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oprymea have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Oprymea are continuously monitored. Side effects reported with Oprymea are carefully evaluated and any necessary action taken to protect patients.

## Other information about Oprymea

Oprymea received a marketing authorisation valid throughout the EU on 12 September 2008.

Information on the reference medicine can also be found on the Agency's website.

Oprymea : EPAR - Medicine overview

English (EN) (76.87 KB - PDF)

**First published:** 22/09/2008

**Last updated:** 20/03/2018

[View](/en/documents/overview/oprymea-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-798)

български (BG) (103.6 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/bg/documents/overview/oprymea-epar-medicine-overview_bg.pdf)

español (ES) (76.11 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/es/documents/overview/oprymea-epar-medicine-overview_es.pdf)

čeština (CS) (100.49 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/cs/documents/overview/oprymea-epar-medicine-overview_cs.pdf)

dansk (DA) (75.23 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/da/documents/overview/oprymea-epar-medicine-overview_da.pdf)

Deutsch (DE) (77.1 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/de/documents/overview/oprymea-epar-medicine-overview_de.pdf)

eesti keel (ET) (74.64 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/et/documents/overview/oprymea-epar-medicine-overview_et.pdf)

ελληνικά (EL) (110.37 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/el/documents/overview/oprymea-epar-medicine-overview_el.pdf)

français (FR) (77.01 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/fr/documents/overview/oprymea-epar-medicine-overview_fr.pdf)

hrvatski (HR) (97.33 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/hr/documents/overview/oprymea-epar-medicine-overview_hr.pdf)

italiano (IT) (75.73 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/it/documents/overview/oprymea-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (98.5 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/lv/documents/overview/oprymea-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (100.06 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/lt/documents/overview/oprymea-epar-medicine-overview_lt.pdf)

magyar (HU) (96.77 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/hu/documents/overview/oprymea-epar-medicine-overview_hu.pdf)

Malti (MT) (109.27 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/mt/documents/overview/oprymea-epar-medicine-overview_mt.pdf)

Nederlands (NL) (75.63 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/nl/documents/overview/oprymea-epar-medicine-overview_nl.pdf)

polski (PL) (100.82 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/pl/documents/overview/oprymea-epar-medicine-overview_pl.pdf)

português (PT) (76.31 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/pt/documents/overview/oprymea-epar-medicine-overview_pt.pdf)

română (RO) (98.85 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/ro/documents/overview/oprymea-epar-medicine-overview_ro.pdf)

slovenčina (SK) (100.93 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/sk/documents/overview/oprymea-epar-medicine-overview_sk.pdf)

slovenščina (SL) (96.22 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/sl/documents/overview/oprymea-epar-medicine-overview_sl.pdf)

Suomi (FI) (75.3 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/fi/documents/overview/oprymea-epar-medicine-overview_fi.pdf)

svenska (SV) (96.98 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

20/03/2018

[View](/sv/documents/overview/oprymea-epar-medicine-overview_sv.pdf)

## Product information

Oprymea : EPAR - Product Information

English (EN) (513.5 KB - PDF)

**First published:** 16/09/2009

**Last updated:** 21/08/2024

[View](/en/documents/product-information/oprymea-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-673)

български (BG) (558.5 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/bg/documents/product-information/oprymea-epar-product-information_bg.pdf)

español (ES) (543.33 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/es/documents/product-information/oprymea-epar-product-information_es.pdf)

čeština (CS) (529.16 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/cs/documents/product-information/oprymea-epar-product-information_cs.pdf)

dansk (DA) (556.89 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/da/documents/product-information/oprymea-epar-product-information_da.pdf)

Deutsch (DE) (511.28 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/de/documents/product-information/oprymea-epar-product-information_de.pdf)

eesti keel (ET) (517.04 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/et/documents/product-information/oprymea-epar-product-information_et.pdf)

ελληνικά (EL) (545.28 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/el/documents/product-information/oprymea-epar-product-information_el.pdf)

français (FR) (607.37 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/fr/documents/product-information/oprymea-epar-product-information_fr.pdf)

hrvatski (HR) (636.46 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/hr/documents/product-information/oprymea-epar-product-information_hr.pdf)

íslenska (IS) (470.16 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/is/documents/product-information/oprymea-epar-product-information_is.pdf)

italiano (IT) (536.71 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/it/documents/product-information/oprymea-epar-product-information_it.pdf)

latviešu valoda (LV) (526.59 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/lv/documents/product-information/oprymea-epar-product-information_lv.pdf)

lietuvių kalba (LT) (494.77 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/lt/documents/product-information/oprymea-epar-product-information_lt.pdf)

magyar (HU) (553.43 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/hu/documents/product-information/oprymea-epar-product-information_hu.pdf)

Malti (MT) (608.64 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/mt/documents/product-information/oprymea-epar-product-information_mt.pdf)

Nederlands (NL) (540.75 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/nl/documents/product-information/oprymea-epar-product-information_nl.pdf)

norsk (NO) (506.48 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/no/documents/product-information/oprymea-epar-product-information_no.pdf)

polski (PL) (541.14 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/pl/documents/product-information/oprymea-epar-product-information_pl.pdf)

português (PT) (530.2 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/pt/documents/product-information/oprymea-epar-product-information_pt.pdf)

română (RO) (551.63 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/ro/documents/product-information/oprymea-epar-product-information_ro.pdf)

slovenčina (SK) (533.34 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/sk/documents/product-information/oprymea-epar-product-information_sk.pdf)

slovenščina (SL) (523.5 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/sl/documents/product-information/oprymea-epar-product-information_sl.pdf)

Suomi (FI) (517.32 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/fi/documents/product-information/oprymea-epar-product-information_fi.pdf)

svenska (SV) (514.08 KB - PDF)

**First published:**

16/09/2009

**Last updated:**

21/08/2024

[View](/sv/documents/product-information/oprymea-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0043 20/08/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Oprymea : EPAR - All Authorised presentations

English (EN) (38.9 KB - PDF)

**First published:** 22/09/2008

**Last updated:** 14/08/2015

[View](/en/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-701)

български (BG) (61.95 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/bg/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_bg.pdf)

español (ES) (38.3 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/es/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52.98 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/cs/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (37.34 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/da/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.98 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/de/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.6 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/et/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (72.42 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/el/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_el.pdf)

français (FR) (37.59 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/fr/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (54.75 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/hr/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (37.9 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/is/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_is.pdf)

italiano (IT) (36.34 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/it/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (57.13 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/lv/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.44 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/lt/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.82 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/hu/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (55.64 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/mt/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (38.34 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/nl/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (38.7 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/no/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_no.pdf)

polski (PL) (59.44 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/pl/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_pl.pdf)

português (PT) (36.52 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/pt/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_pt.pdf)

română (RO) (53.87 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/ro/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (55.88 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/sk/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.04 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/sl/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (37.85 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/fi/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (36.05 KB - PDF)

**First published:**

22/09/2008

**Last updated:**

14/08/2015

[View](/sv/documents/all-authorised-presentations/oprymea-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Oprymea Active substance pramipexole dihydrochloride monohydrate International non-proprietary name (INN) or common name pramipexole Therapeutic area (MeSH) Parkinson Disease Anatomical therapeutic chemical (ATC) code N04BC05

### Pharmacotherapeutic group

Anti-Parkinson drugs

### Therapeutic indication

Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or \"on off\" fluctuations).

Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).

## Authorisation details

EMA product number EMEA/H/C/000941

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Krka, d.d., Novo mesto

Šmarješka cesta 6

Marketing authorisation issued 12/09/2008 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Oprymea : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (155.87 KB - PDF)

**First published:** 16/09/2009

**Last updated:** 21/08/2024

[View](/en/documents/procedural-steps-after/oprymea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Oprymea-H-C-941-X-0014 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/703661/2013

English (EN) (737.32 KB - PDF)

**First published:** 13/01/2014

**Last updated:** 13/01/2014

[View](/en/documents/variation-report/oprymea-h-c-941-x-0014-epar-assessment-report-extension_en.pdf)

## Initial marketing authorisation documents

Oprymea : EPAR - Public assessment report

English (EN) (216.88 KB - PDF)

**First published:** 23/09/2008

**Last updated:** 23/09/2008

[View](/en/documents/assessment-report/oprymea-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Oprymea

Reference Number: EMEA/CHMP/313494/2008

English (EN) (32.68 KB - PDF)

**First published:** 26/06/2008

**Last updated:** 26/06/2008

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-oprymea_en.pdf)

#### More information on Oprymea

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/08/2024

## Share this page

[Back to top](#main-content)